|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bade BC and Dela Cruz CS: Lung cancer
2020: Epidemiology, etiology, and prevention. Clin Chest Med.
41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Šutić M, Vukić A, Baranašić J, Försti A,
Džubur F, Samaržija M, Jakopović M, Brčić L and Knežević J:
Diagnostic, predictive, and prognostic biomarkers in non-small cell
lung cancer (NSCLC) management. J Pers Med. 11:11022021. View Article : Google Scholar
|
|
4
|
Nicholson AG, Tsao MS, Beasley MB, Borczuk
AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S,
et al: The 2021 WHO classification of lung tumors: Impact of
advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina H,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang F, Wang C, Yang P, Sun P and Liu J:
Pathological cytomorphologic features and the percentage of ALK
FISH-positive cells predict pulmonary adenocarcinoma prognosis: A
prospective cohort study. World J Surg Oncol. 19:2782021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hofman P: ALK in non-small cell lung
cancer (NSCLC) pathobiology, epidemiology, detection from tumor
tissue and algorithm diagnosis in a daily practice. Cancers.
9:1072017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyata K, Morita S, Dejima H, Seki N,
Matsutani N, Mieno M, Kondo F, Soejima Y, Tanaka F and Sawabe M:
Cytological markers for predicting ALK-positive pulmonary
adenocarcinoma. Diagn Cytopathol. 45:963–970. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshida A, Tsuta K, Nakamura H, Kohno T,
Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K
and Tsuda H: Comprehensive histologic analysis of ALK-rearranged
lung carcinomas. Am J Surg Pathol. 35:1126–1134. 2011. View Article : Google Scholar
|
|
10
|
Nishino M, Klepeis VE, Yeap BY, Bergethon
K, Morales-Oyarvide V, Dias-Santagata D, Yagi Y, Mark EJ, Iafrate
AJ and Mino–Kenudson M: Histologic and cytomorphologic features of
ALK-rearranged lung adenocarcinomas. Mod Pathol. 25:1462–1472.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pareja F, Crapanzano JP, Mansukhani MM,
Bulman WA and Saqi A: Cytomorphological features of ALK-positive
lung adenocarcinomas: Psammoma bodies and signet ring cells. Cancer
Cytopathol. 123:162–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ha SY, Ahn J, Roh MS, Han J, Lee JJ, Lee B
and Yim J: Cytologic features of ALK-positive pulmonary
adenocarcinoma. Korean J Pathol. 47:252–257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Russo A, Franchina T, Riccardi GRR, Picone
A, Ferraro G, Zanghi M, Toscano G, Giordano A and Adamo V: A decade
of EGFR inhibition in EGFR-mutated non-small cell lung cancer
(NSCLC): Old successes and future perspectives. Oncotarget.
6:26814–26825. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharma S, Gupta N, Singh N, Chaturvedi R,
Behera D and Rajwanshi A: Cytomorphological features as predictors
of epidermal growth factor receptor mutation status in lung
adenocarcinoma. Cytojournal. 15:112018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dacic S, Shuai Y, Yousem S, Ohori P and
Nikiforova M: Clinicopathological predictors of EGFR/KRAS
mutational status in primary lung adenocarcinomas. Mod Pathol.
23:159–168. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang
Y, Li H, Ye T, Zhang Y, Luo X, et al: Oncogenic mutations are
associated with histological subtypes but do not have an
independent prognostic value in lung adenocarcinoma. Onco Targets
Ther. 7:1423–1437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kobayashi Y, Yokose T, Kawamura K, Iwasaki
S, Murata Y, Onuma S, Hasebe T, Nagai K, Sasaki S and Ochiai A:
Cytologic factors associated with prognosis in patients with
peripheral adenocarcinoma of the lung measuring 3 cm or less in
greatest dimension. Cancer. 105:44–51. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ravaioli S, Bravaccini S, Tumedei MM,
Pironi F, Candoli P and Puccetti M: Easily detectable
cytomorphological features to evaluate during ROSE for rapid lung
cancer diagnosis: From cytology to histology. Oncotarget.
8:11199–11205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Radić J, Nikolić I, Kolarov-Bjelobrk I,
Vasiljević T, Djurić A, Vidović V and Kožik B: Prognostic and
predictive significance of primary tumor localization and HER2
expression in the treatment of patients with KRAS wild-type
metastatic colorectal cancer: Single-centre experience from serbia.
J Pers Med. 14:8792024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marotti JD, Schwab MC, McNulty NJ, Rigas
JR, DeLong PA, Memoli VA, Tsongalis GJ and Padmanabhan V:
Cytomorphologic features of advanced lung adenocarcinomas tested
for EGFR and KRAS mutations: A retrospective review of 50 cases.
Diagn Cytopathol. 41:15–21. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noronha V, Ramaswamy A, Patil VM, Joshi A,
Chougule A, Kane S, Kumar R, Sahu A, Doshi V, Nayak L, et al: ALK
positive lung cancer: clinical profile, practice and outcomes in a
developing country. PLoS One. 11:e01607522016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou X, Chen H, Liu Y, Gong S, Zhudai M and
Shen L: Clinicopathological and computed tomography features of
patients with early-stage non-small-cell lung cancer harboring ALK
rearrangement. Cancer Imaging. 23:202023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kang HJ, Lim HJ, Park JS, Cho YJ, Yoon HI,
Chung JH, Lee JH and Lee CT: Comparison of clinical characteristics
between patients with ALK-positive and EGFR-positive lung
adenocarcinoma. Respir Med. 108:388–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Q, Huang Q, Yu Z and Wu H: Clinical
characteristics of non-small cell lung cancer patients with EGFR
mutations and ALK&ROS1 fusions. Clin Respir J. 16:216–225.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou JY, Zheng J, Yu ZF, Xiao WB, Zhao J,
Sun K, Wang B, Chen X, Jiang LN, Ding W and Zhou JY: Comparative
analysis of clinicoradiologic characteristics of lung
adenocarcinomas with ALK rearrangements or EGFR mutations. Eur
Radiol. 25:1257–1266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mourabiti AY, Sqalli Houssaini M, Benfares
A, Bouardi NE, Lamrani MYA, Fatemi HE, Serraj M, Amara B, Qjidaa H,
Smahi M, et al: Clinical and radiological features associated with
EGFR mutation in non-small-cell lung cancer: A study of 149 cases.
Egypt J Radiol Nucl Med. 54:1712023. View Article : Google Scholar
|
|
27
|
Tsuta K, Ishii G, Yoh K, Nitadori J-I,
Hasebe T, Nishiwaki Y, Endoh Y, Kodama T, Nagai K and Ochiai A:
Primary lung carcinoma with signetring cell carcinoma components:
Clinicopathological analysis of 39 cases. Am J Surg Pathol.
28:868–874. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boland JM, Wampfler JA, Jang JS, Wang X,
Erickson–Johnson MR, Oliveira AM, Yang P, Jen J and Yi ES:
Pulmonary adenocarcinoma with signet ring cell features: A
comprehensive study from 3 distinct patient cohorts. Am J Surg
Pathol. 38:1681–1688. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miyata-Morita K, Morita S, Matsutani N,
Kondo F, Soejima Y and Sawabe M: Frequent appearance of club cell
(Clara cell)-like cells as a histological marker for ALK-positive
lung adenocarcinoma. Pathol Int. 69:688–696. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blons H, Côté JF, Le Corre D, Riquet M,
Fabre-Guilevin E, Laurent-Puig P and Danel C: Epidermal growth
factor receptor mutation in lung cancer are linked to
bronchioloalveolar differentiation. Am J Surg Pathol. 30:1309–1315.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song Z, Liu T, Shi L, Yu Z, Shen Q, Xu M,
Huang Z, Cai Z, Wang W, Xu C and Sun J: The deep learning model
combining CT image and clinicopathological information for
predicting ALK fusion status and response to ALK-TKI therapy in
non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging.
48:361–371. 2021. View Article : Google Scholar : PubMed/NCBI
|
